129 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
7 May 24
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7:03am
and leading to mitotic catastrophe and cancer cell death.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
in mitotic catastrophe and cell death CDKs and their cyclin binding partners promote progression through the cell cycle Following DNA damage, WEE1 … DNA damage accumulates Cancer Cell Mitotic Catastrophe and Death DNA damage P CDK2 Active/Not phosphorylated CDKCyclin CDKCyclin Azenosertib WEE1
8-K
EX-99.1
l9d1z
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
8-K
EX-3.1
fllp w0dk5c3h1gh84
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm
8-K
EX-99.1
02qo41sq8ydefa1jr
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.2
gjy74h8i
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
n7cfg
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
brluz
9 Aug 23
Regulation FD Disclosure
4:15pm